ClinicalTrials.gg
Status unknownNCT02868801EASOPSRTFPUpdated Aug 16, 2016

Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia

A Phase 3 interventional study of Placebo and Pregabalin SR tablet 165mg/day in Postherpetic Neuralgia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 27 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-08-16.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing pregabalin in Neuralgia, Postherpetic — 3 open to participants now, 3 under way, 1 of them phase 3. Pregabalin · Neuralgia, Postherpetic.

Planned enrollment
4th of 15
280 · median 126
Started
2015
the only one that year
Phase 3
5 of 15
1 open now
Registered
12th of 15
by date
Lead sponsor
1 of 15
Jiangsu HengRui Medicine Co., Ltd.

Among the 15 studies testing pregabalin in Neuralgia, Postherpetic, this one is the 4th largest by planned enrollment, is the only one that started in 2015, is one of 5 in phase 3, and was the 12th registered.

Neuralgia, Postherpetic

197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.

Browse Neuralgia, Postherpetic studies →

Open to participants now

3 of the 15 studies testing pregabalin in Neuralgia, Postherpetic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing pregabalin in Neuralgia, Postherpetic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the Efficacy and safety of pregabalin sustained release tablet versus placebo for postherpetic neuralgia.

Read the detailed description

This is a randomized, double-blind, multicenter, placebo-controlled trial to compare the efficacy and safety of pregabalin SR vs placebo in patients with PHN.

The study is conducting at 27 study centers in China. Patients were randomized to receive pregabalin, starting at 165 mg/day and increasing to a maintenance dose of 330 or 660 mg/day, or placebo.

The study includes a 1-week, single-blind, placebo run-in period; a 2-week dose-escalation/optimization phase; a 12-week, fixed-dose treatment period; and a 1-week taper phase.

03

Conditions studied

  • Postherpetic Neuralgia

Keywords

  • Pregabalin
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Outpatient ,Patients can not stay in the hospital overnight;
  2. Patients must have pain present for more than 3 months after the healing of the herpes zoster skin rash;
  3. At least 4 days and at least 8 pain diaries(Pain Numeric Rating Scale) must be completed satisfactorily within the seven days of single-blind, placebo run-in period, and the average pain score must be greater than or equal to 4;
  4. At screening (V0) and enrollment (V1), patients must have a score of greater than or equal to 40 mm on the 100 mm pain visual analog scale;
  5. Women were neither pregnant nor lactating, and those of childbearing age had a confirmed negative serum pregnancy test at baseline and practiced an appropriate method of throughout the study.

Exclusion criteria

Exclusion Criteria:

  1. Decrease of ≥30% on their pain VAS or ≥ 4 between any two pain diaries during the placebo run-in period.( in order to remove potential placebo-responders);
  2. Patients who had failed to respond to previous treatment for PHN with gabapentin at doses ≥1200 mg/day ;
  3. History of using pregabalin or participation in a previous trial of pregabalin;
  4. Patients with a skin condition or severe non-PHN pain that might impair the self assessment of pain caused by PHN;
  5. Patients with other Nervous system disorders which might impair completing the pain diaries or sleep interference diaries;
  6. History of epilepsy and being treated by drug therapy;
  7. Previous surgical therapy for PHN;
  8. History of using effective therapies during 2 weeks before screening (V0),eg: acupuncture and moxibustion, Transcutaneous Electrical Nerve Stimulation;
  9. Potentially retinal toxicity of drugs past or now;
  10. Prohibited medications without appropriate ;
  11. within the past 2 years;
  12. Laboratory examination: WBC\<2.5×109/L;ANC\<1.5×109/L;\<100×109/L;/AST>3ULN;
  13. ≤ 60 mL/min;
  14. Positive antibody of , ,Treponema pallidum ;
  15. Patients who are allergic to or intolerant of pregabalin or other drugs which have a similarly chemical structure ;
  16. History of illicit drug or alcohol abuse within the last 2 years;
  17. or unstable hepatic, respiratory, or hematologic illnesses or psychologic conditions; unstable cardiovascular disease which may increase the risk of participation the clinical trial in the opinion of the study investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
280 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    placebo, oral administration for 14 weeks (2 week titration and 12-week fixed dose)

    Drug: Placebo

  • Experimental
    Pregabalin SR tablet 165mg/day

    1pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)

    Drug: Pregabalin SR tablet 165mg/day

  • Experimental
    Pregabalin SR tablet 330mg/day

    1pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)

    Drug: Pregabalin SR tablet 330mg/day

  • Experimental
    Pregabalin SR tablet 660mg/day

    2pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)

    Drug: Pregabalin SR tablet 660mg/day

Interventions

  • DrugPlacebo

    same intervention as the experimental group

    Also known as: Placebo tablet of pregabalin sustained release tablet

  • DrugPregabalin SR tablet 165mg/day

    Drug page: Pregabalin

    According to the efficacy and safety in titration

    Also known as: Pregabalin sustained release tablet

  • DrugPregabalin SR tablet 330mg/day

    Drug page: Pregabalin

    According to the efficacy and safety in titration

    Also known as: Pregabalin sustained release tablet

  • DrugPregabalin SR tablet 660mg/day

    Drug page: Pregabalin

    According to the efficacy and safety in titration.

    Also known as: Pregabalin sustained release tablet

06

What researchers measure

Primary outcomes

  1. Number of Responders

    A responder is defined as a subject with a 30% reduction in weekly mean pain score from baseline to endpoint

    Time frame: 15 weeks

Secondary outcomes

  1. 50% reduction in weekly mean pain score from baseline to study completion

    Time frame: 15 weeks

  2. Change of Mean Pain Scores from study completion to baseline

    Time frame: 15 weeks

  3. Change of Mean Sleep Interference Scores from study completion to baseline

    Time frame: 15 weeks

07

Study locations

27 of 27 sites recruiting
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
    Recruiting
  • Beijing Chao-yang Hospital
    Beijing, Beijing, China
    Recruiting
  • Beijing Friendship Hospital ,Capital Medical University
    Beijing, Beijing, China
    Recruiting
  • China-Japan Friendship Hospital
    Beijing, Beijing, China
    Recruiting
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian, China
    Recruiting
  • Sun Yat-Sen Memory Hospital , Sun Yat-Sen University
    Guangzhou, Guangdong, China
    Recruiting
  • The Affiliated Hospital of Guizhou Medical University
    Guiyang, Guizhou, China
    Recruiting
  • The Affiliated Hospital of Hainan Medical College
    Haikou, Hainan, China
    Recruiting
  • Fourth Hospital Of Hebei Medical University
    Shijiazhuang, Hebei, China
    Recruiting
  • The Second Hospital Of Hebei Medical University
    Shijiazhuang, Hebei, China
    Recruiting
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
    Recruiting
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
    Recruiting
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
    Recruiting
  • Yancheng City NO.1 People's Hospital
    Yancheng, Jiangsu, China
    Recruiting
  • The Affiliated Hospital of Jilin University
    Changchun, Jilin, China
    Recruiting
  • Shengjing Hospital Of China Medical University
    Shengyang, Liaoning, China
    Recruiting
  • The People's Hospital of Liaoning Province
    Shenyang, Liaoning, China
    Recruiting
  • Qingdao Municipal Hospital(Group)
    Qingdao, Shandong, China
    Recruiting
  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai, China
    Recruiting
  • First Hospital Of Shanxi Medical University
    Taiyuan, Shanxi, China
    Recruiting
  • Second Hospital Of Shanxi Medical University
    Taiyuan, Shanxi, China
    Recruiting
  • Xijing Hospital; the Fourth Military Medical University
    Xi'an, Shanxi, China
    Recruiting
  • People's Hospital of Xinjiang Uygur Autonomous Region
    Wulumuqi, Xinjiang, China
    Recruiting
  • Xinjiang Uygur Autonomous Region Hospital OF TCM
    Wulumuqi, Xinjiang, China
    Recruiting
  • First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
    Recruiting
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang, China
    Recruiting
  • The First Affiliated Hospital , Zhejiang University
    Hangzhou, Zhejiang, China
    Recruiting
08

References and documents

Publications

  • van Seventer R, Feister HA, Young JP Jr, Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin. 2006 Feb;22(2):375-84. doi: 10.1185/030079906x80404. PubMed 16466610 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2015
First posted
Aug 16, 2016
Start
Mar 2015
Primary completionEst.
Jun 2017
CompletionEst.
Jun 2017
Last update
Aug 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02868801
Responsible party
Sponsor
First posted
Aug 16, 2016
Start date
Mar 2015
Primary completion
Jun 2017 (estimated)
Completion
Jun 2017 (estimated)
Last update
Aug 16, 2016

Study contacts

Liang Yunsheng, M.D.
Contact
liangyunsheng@hotmail.com
UN
Lu Qianjin, M.D.
Contact
qianlu5860@gmail.com
13787097676
Lu Qianjin, M.D.
principal investigator · Central South University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion